Hirofumi Yamada

Tokyo, 1138510, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Sequential [11C]Acetate and [18F]FDG PET/CT Assessment of Systemic Chronic Active Epstein-Barr Virus Disease: An Exploratory Retrospective Study.

Sequential [11C]Acetate and [18F]FDG PET/CT Assessment of Systemic Chronic Active Epstein-Barr Virus Disease: An Exploratory Retrospective Study.

Journal: Diagnostics (Basel, Switzerland)

Published: May 21, 2026

No-carrier-added 177Lu production eliminates persistent urine radioactivity: implications for safe expansion of targeted radionuclide therapy.

No-carrier-added 177Lu production eliminates persistent urine radioactivity: implications for safe expansion of targeted radionuclide therapy.

Journal: Annals of nuclear medicine

Published: May 12, 2026

Seeing the invisible: practical strategies to maximize the clinical impact of photon-counting CT in abdominal imaging.

Seeing the invisible: practical strategies to maximize the clinical impact of photon-counting CT in abdominal imaging.

Journal: Abdominal radiology (New York)

Published: April 28, 2026

Lesion conspicuity assessment of prone 40-keV virtual monoenergetic imaging in arterial-phase photon-counting CT for breast cancer: a retrospective comparison with DCE-MRI.

Lesion conspicuity assessment of prone 40-keV virtual monoenergetic imaging in arterial-phase photon-counting CT for breast cancer: a retrospective comparison with DCE-MRI.

Journal: Japanese journal of radiology

Published: December 30, 2025

Transient bradycardia during 177Lu-DOTATATE therapy: A clinically manageable phenomenon with increased risk in patients with cardiac enlargement.

Transient bradycardia during 177Lu-DOTATATE therapy: A clinically manageable phenomenon with increased risk in patients with cardiac enlargement.

Journal: Annals of nuclear medicine

Published: September 16, 2025

Comparison of MRI-, CT- and PET-based anatomical standardization for Centiloid scale calculation in [18F]florbetapir positron emission tomography.

Comparison of MRI-, CT- and PET-based anatomical standardization for Centiloid scale calculation in [18F]florbetapir positron emission tomography.

Journal: Annals of nuclear medicine

Published: May 06, 2025

Breast cancer seeding in the biopsy route observed on preoperative imaging.

Breast cancer seeding in the biopsy route observed on preoperative imaging.

Journal: BMJ case reports

Published: June 23, 2021

Late-onset pneumothorax in a COVID-19 patient treated with ventilation and ECMO: A case report and literature review.

Late-onset pneumothorax in a COVID-19 patient treated with ventilation and ECMO: A case report and literature review.

Journal: Radiology case reports

Published: August 21, 2020

Evaluation of the Usefulness of CO-RADS for Chest CT in Patients Suspected of Having COVID-19.

Evaluation of the Usefulness of CO-RADS for Chest CT in Patients Suspected of Having COVID-19.

Journal: Diagnostics (Basel, Switzerland)

Published: July 16, 2020

Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).

Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).

Journal: Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

Published: July 12, 2019

TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.

TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.

Journal: Investigational new drugs

Published: April 29, 2019

Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Journal: Investigational new drugs

Published: April 27, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026